8-KOther Events

QUEST DIAGNOSTICS INC 8-K Report, Corporate Update (Mar 31, 2020)

Filed March 31, 2020For Securities:DGX

Summary

Quest Diagnostics (DGX) filed this 8-K on March 31, 2020, to update investors on the material impact of the COVID-19 pandemic on its business. The company has made significant investments to expand COVID-19 testing capacity, performing over 30,000 tests daily. However, the pandemic has led to a substantial decline in overall testing volumes, exceeding 40% in the latter half of March, due to reduced physician visits and elective procedures. Consequently, Quest Diagnostics is withdrawing its previously issued 2020 financial guidance. The full extent of the adverse impact on operating results, cash flows, and financial condition remains uncertain due to the unpredictable nature of the pandemic's severity, duration, and governmental responses. The company plans to provide further updates on the pandemic's impact during its first quarter 2020 earnings release on April 22, 2020.

Key Highlights

  • 1Quest Diagnostics is significantly expanding its COVID-19 testing capacity, performing over 30,000 tests daily.
  • 2The company is experiencing a material decline in overall testing volumes, exceeding 40% in late March, due to the COVID-19 pandemic.
  • 3Factors contributing to volume decline include reduced physician visits, canceled elective procedures, and operational impacts on customers.
  • 4Quest Diagnostics is withdrawing its previously issued full-year 2020 financial guidance due to uncertainty.
  • 5The company cannot currently estimate the full adverse impact of the COVID-19 pandemic on its financial results.
  • 6Operational continuity plans are in place, with many office-based employees transitioned to remote work.
  • 7First quarter 2020 results and further pandemic impact updates will be provided on April 22, 2020.

Frequently Asked Questions

This filing is to inform investors about the significant and ongoing impact of the COVID-19 pandemic on Quest Diagnostics' business operations, including testing volumes and financial outlook.

Quest Diagnostics is increasing its capacity to perform COVID-19 tests, handling over 30,000 tests daily, and has implemented operational preparedness plans to ensure business continuity while prioritizing the health and safety of its employees and customers.

The company is experiencing a material decline in testing volumes (over 40% in late March) and has withdrawn its 2020 financial guidance. The full adverse impact on operating results and cash flows is uncertain and is expected to be material.

Quest Diagnostics expects to release its first quarter 2020 financial results on April 22, 2020, at which time it will provide further updates on the impact of the COVID-19 pandemic.